147 related articles for article (PubMed ID: 23362550)
1. [What is exactly alike? High-performance analytics for development of biosimilars].
Blüggel M
Pharm Unserer Zeit; 2012 Nov; 41(6):468-73. PubMed ID: 23362550
[No Abstract] [Full Text] [Related]
2. Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilars.
Nicholson R; Lowes S; Caturla MC; Safavi A; Mamelak D; Islam R; Allinson J; Gouty D; Khan M; Lelacheur R; Shoup R; Martinez S; Dumont I; Zimmer J; Steffen R; Petrilla J; Awaiye K; Sheldon C; Turk D; Fast D; Kamerud J; Dinan A; Lin ZJ; Garofolo W; Tang D; Wright L; Lin J; Yamashita Y; Liu Y; Xu A; Hayes R; Bouhajib M; Levesque A; Gagnon-Carignan S; Harman J; Warren M; Karnik S; Cojocaru L; Reuschel S; Gonzalez P; Fatmi S; Vija J; Rock M; Malone M; Nowatzke W; Fang X
Bioanalysis; 2012 Oct; 4(19):2335-42. PubMed ID: 23088460
[No Abstract] [Full Text] [Related]
3. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
4. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.
Blauvelt A; Cohen AD; Puig L; Vender R; van der Walt J; Wu JJ
Br J Dermatol; 2016 Feb; 174(2):282-6. PubMed ID: 26522054
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
7. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
Hakim A; Ross JS
JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
[No Abstract] [Full Text] [Related]
8. Analytical detection and characterization of biopharmaceutical glycosylation by MS.
Oh MJ; Hua S; Kim U; Kim HJ; Lee J; Kim JH; An HJ
Bioanalysis; 2016 Apr; 8(7):711-27. PubMed ID: 26964748
[TBL] [Abstract][Full Text] [Related]
9. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
10. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.
Háda V; Bagdi A; Bihari Z; Timári SB; Fizil Á; Szántay C
J Pharm Biomed Anal; 2018 Nov; 161():214-238. PubMed ID: 30205300
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
12. Challenges in bioanalytical assays for biosimilars.
Wang X; Chen L
Bioanalysis; 2014 Aug; 6(16):2111-3. PubMed ID: 25331854
[No Abstract] [Full Text] [Related]
13. Mini Focus: bioanalysis of biosimilars.
Amaravadi L; Marini J
Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
[No Abstract] [Full Text] [Related]
14. Biologics and biosimilars.
Patel PK; King CR; Feldman SR
J Dermatolog Treat; 2015; 26(4):299-302. PubMed ID: 26105205
[TBL] [Abstract][Full Text] [Related]
15. European Medicines Agency guidelines to increase the pace of biosimilar development.
Parks L
Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
[No Abstract] [Full Text] [Related]
16. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry.
David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L
Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600
[TBL] [Abstract][Full Text] [Related]
17. Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).
Oldfield P
Bioanalysis; 2011 Jul; 3(14):1551-3. PubMed ID: 21756087
[No Abstract] [Full Text] [Related]
18. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
19. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Buske C; Ogura M; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
[TBL] [Abstract][Full Text] [Related]
20. Analysis of biological therapeutic agents and biosimilars.
Phinney K
Anal Bioanal Chem; 2014 Oct; 406(26):6539. PubMed ID: 25190012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
